Personal information

Countries

Russia

Activities

Collapse all

Employment (1)

PJSC Valenta Pharm: Moscow, RU

2018-06 to present | Head of Preclinical trials department (Preclinical trials department )
Employment
Source: Self-asserted source
Ekaterina Jain

Education and qualifications (2)

Lomonosov Moscow State University: Moscow, RU

2017 to 2020 | PhD student (Faculty of fundamental medicine )
Education
Source: Self-asserted source
Ekaterina Jain

Lomonosov Moscow State University: Moscow, RU

2011 to 2017 (Faculty of fundamental medicine )
Education
Source: Self-asserted source
Ekaterina Jain

Works (10)

Preclinical Evaluation of Esomeprazole Safety and Toxicokinetics

Safety and Risk of Pharmacotherapy
2023-05-18 | Journal article
DOI: 10.30895/2312-7821-2023-11-2-342
Contributors: V. M. Kosman; M. V. Karlina; E. V. Mazukina; A. A. Globenko; E. A. Jain; M. N. Makarova; V. G. Makarov
Source: check_circle
Crossref

Toxicity profile of the new compound XC221GI from pre-clinical studies

Epidemiology and Infectious Diseases
2022-08-19 | Journal article
DOI: 10.17816/EID108910
Contributors: Svetlana A. Suhanova; Oksana V. Proskurina; Ekaterina A. Jain; Aleksander A. Globenko; Madina I. Bagaeva; Anastasia V. Rydlovskaya; Vladimir E. Nebolsin
Source: check_circle
Crossref

Investigation of the pharmacokinetics of an original drug for the treatment of HIV-1 infection

Farmaciya (Pharmacy)
2021 | Journal article
DOI: 10.29296/25419218-2021-04-08
Contributors: Vera Mikhaylovna Kosman; Dmitry Valentinovich Demchenko; Ekaterina Aleksandrovna Jain; Valeriy Gennadievich Makarov; Vadim Yur'evich Balabaniyan
Source: check_circle
Crossref

Evaluation of mutagenicity, genotoxicity and chronic toxicity of antiviral drug imidazolyl ethanamide pentandioic acid in <i>in vitro</i> and <i>in vivo</i> test systems

Journal of microbiology, epidemiology and immunobiology
2021-11-02 | Journal article
DOI: 10.36233/0372-9311-180
Contributors: E. A. Jain; D. Pleimes; A. A. Globenko
Source: check_circle
Crossref

Study of the specific toxic effects of the substance 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil, the original non-nucleoside inhibitor of human immunodeficiency virus type 1 (Retroviridae; Orthoretrovirinae; Lentivirus: Human immunodeficiency virus 1) reverse transcriptase

Problems of Virology
2021-09-18 | Journal article
DOI: 10.36233/0507-4088-59
Contributors: E. A. Gaidai; K. L. Kryshen; E. A. Jain (Korsakova); D. V. Demchenko; D. R. Kargopol’tseva; A. E. Katel’nikova; D. S. Gaidai; V. Yu. Balabanyan
Source: check_circle
Crossref

EXPERIMENTAL STUDY OF TOXIC PROPERTIES OF VMU-2012-05 DRUG – ORIGINAL NON-NUCLEESIDE INHIBITOR OF HIV-1 REVERSE TRANSCRIPTASE

Pharmacy & Pharmacology
2021-08-19 | Journal article
DOI: 10.19163/2307-9266-2021-9-3-205-221
Contributors: V. A. Vavilova; E. V. Shekunova; E. A. Jain (Korsakova); V. Yu. Balabanyan; A. A. Ozerov; M. N. Makarova; V. G. Makarov
Source: check_circle
Crossref

CHARACTERISATION AND STUDY OF 1- [2- (2-BENZOYLPHENOXY) ETHYL] -6-METHYLURACIL MECHANISM OF ACTION

Pharmacy & Pharmacology
2021-07-20 | Journal article
DOI: 10.19163/2307-9266-2021-9-2-114-129
Contributors: E. A. Jain (Korsakova); D. V. Demchenko; A. A. Ozerov; M. N. Makarova; V. G. Makarov; V. Yu. Balabanyan
Source: check_circle
Crossref

Comparative Pharmacokinetics Study of 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil Substance and its Solid Dispersion Systems on Rabbits

Drug development & registration
2021-05-29 | Journal article
DOI: 10.33380/2305-2066-2021-10-2-106-111
Contributors: V. M. Kosman; D. V. Demchenko; E. A. Jain (Korsakova); V. G. Makarov; V. Yu. Balabanyan
Source: check_circle
Crossref

Pharmacokinetics of Pentanedioic Acid Imidazolyl Ethanamide in Healthy Volunteers

Antibiotics and Chemotherapy
2021-05-06 | Journal article
DOI: 10.37489/0235-2990-2021-66-1-2-19-25
Contributors: I. G. Gordeev; V. I. Kazey; A. V. Kapashin; E. Е. Luchinkina; A. A. Globenko; А. L. Vladykin; E. A. Jain; A. I. Cherenkova; I. A. Kokorin; N. N. Levchuk et al.
Source: check_circle
Crossref

Development and Biopharmaceutical Evaluation of Tablets Based on the Poorly Water-soluble Substance 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil

Drug development & registration
2020-11-26 | Journal article
DOI: 10.33380/2305-2066-2020-9-4-79-87
Contributors: D. V. Demchenko; E. A. Jain (Korsakova); V. Yu. Balabanyan; M. N. Makarova; V. G. Makarov
Source: check_circle
Crossref
How many people are using ORCID?